REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Protocols
5

TB-500 dosage timing question

Crew Hudson·21 days ago
Looking for input from experienced users on this topic. I have done a lot of reading but wanted to get real-world perspectives from people who have actually tried different approaches. What has worked best for you?

Comments (8)

Onyx HughesDEMO·3 months ago

Great write-up! This matches my experience almost exactly. The dosing you mentioned is what I settled on too after some experimentation.

2
Zion BlakeDEMO·2 months ago

Great write-up! This matches my experience almost exactly. The dosing you mentioned is what I settled on too after some experimentation.

2
Hart ChenDEMO·about 2 months ago

Great write-up! This matches my experience almost exactly. The dosing you mentioned is what I settled on too after some experimentation.

2
Jude HoganDEMO·about 1 month ago

Great write-up! This matches my experience almost exactly. The dosing you mentioned is what I settled on too after some experimentation.

2
Dale BanksDEMO·21 days ago

I split my TB-500 dose into two injections per week rather than one larger dose. Anecdotally it seemed to provide more consistent results for my elbow tendinopathy. The half-life data suggests it should not matter much but I noticed less of a rollercoaster effect.

0
Hayden ArcherDEMO·21 days ago

Morning vs evening dosing - has anyone compared? I have been doing AM injections because I read somewhere that tissue repair signaling is more active during sleep. So getting the TB-500 circulating before bed might be counterproductive? Or does it even matter at its half-life?

0
Brook AshfordDEMO·20 days ago

The loading phase discussion is important. I did 4 weeks at 5mg/week then dropped to 2.5mg/week maintenance. The loading phase seemed necessary - I did not notice much until week 3 of the higher dose. Skipping it might mean slower onset of results.

0
Cloud BaileyDEMO·19 days ago

One thing worth adding - I found SubQ abdomen gave me better systemic distribution than intramuscular for TB-500 specifically. With BPC-157 I prefer local injection near the injury, but TB-500 seems to work systemically regardless of site.

0

Sign in to comment.